Salt AI’s collaborative, visual-first platform gives life science and health tech teams clarity, control, and speed to turn complex AI models into production-ready workflows in record time

Salt AI, the leader in contextual AI for enterprise applications in life sciences and health tech, today announced a $10 million funding round, led by Morpheus Ventures, with participation from Struck Capital, Marbruck Investments and CoreWeave. The company will use the capital to expand its customer footprint with leading biopharma and healthcare companies investing in the cutting edge of AI innovation, while also scaling their global AI engineering teams to accelerate delivery and impact. Customers are already deploying Salt Ai across drug discovery, clinical development, revenue cycle management, intelligent data navigation, and enterprise operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916233836/en/

Aber Whitcomb, CEO / Co-Founder of Salt AI

“Salt AI is the kind of company CoreWeave aims to support, applying AI to one of society’s most urgent challenges,” said Brian Venturo, Co-founder and Chief Strategy Officer, CoreWeave. “Our AI cloud platform is purpose-built for complex models, enabling Salt Ai to run workloads quickly and reliably and giving life sciences companies a practical way to integrate AI into everyday research.”

Salt AI is the definitive contextual AI platform that unpacks the “black box” of enterprise AI applications for pharmaceutical, biotech, and healthcare organizations. Its visual‑first interface with full code capabilities transforms how companies build, deploy, and scale AI‑powered workflows across the value chain.

“We are in the midst of a breakthrough moment in life sciences, with AI igniting unprecedented opportunities that were once out of reach,” said Aber Whitcomb, CEO and Co-Founder of Salt AI. “No single AI model can unlock the future of medicine alone. The future belongs to ensembles, models working in synergy. At Salt AI, our platform is designed so organizations can rapidly create, launch, and scale AI solutions that drive healthcare innovation forward. We’re proud that a growing roster of major enterprises already relies on us to reach new milestones in discovery and improve real-world outcomes across the industry.”

The impact is already evident at the Ellison Medical Institute (EMI), where Salt AI has been accelerating breakthroughs in computational biology since summer 2024. EMI is leveraging the Salt AI platform to significantly accelerate drug discovery, enabling the design and analysis of thousands of compounds, and the advancement of two promising protein candidates to in-depth wet-lab studies based on positive in vitro results as of August 2025. Its fast and flexible workflow capabilities enable EMI to continuously refine and enhance its in silico design approach.

“Salt AI represents a transformative advance in the computational biology stack,” said Dr. David Agus, Founding CEO of the Ellison Medical Institute. “By combining drag‑and‑drop workflows with transparent AI integration, the platform enables a new paradigm of therapeutic design, one that is faster, more efficient, and highly data-driven.”

At the center of the platform is the Salt Matrix, a comprehensive catalogue of sector-specific data connectors, models and solutions that enable teams to rapidly build AI workflows with intuitive drag-and-drop tools. Salt AI delivers value to teams through three key pillars:

• Visual Collaboration: Scientists, technologists, and executives work together in real time, solving the “bilingual talent” gap.
• Speed to Value: Private cloud or on-prem environments deployed in days, with customers seeing benefits immediately.
• Trusted Compliance & Scale: A fully compliant stack that integrates proprietary data, workflows, and models, enabling enterprise-grade adoption.

About Salt AI

Salt AI is the collaborative operating system for life sciences, enabling research and healthcare teams to rapidly integrate, visualize, and deploy AI models. From protein generation and biomarker discovery to clinical evidence synthesis and diagnostics, Salt AI combines enterprise-grade scalability with a visual-first interface, empowering cross-functional teams to accelerate discovery and innovation. Founded by successful serial entrepreneurs with a track record of building category-defining platforms, Salt AI is redefining how AI supports discovery and care at scale.

To learn more or request a demo, visit: www.Salt.Ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20250916233836/en/